{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,2,17]],"date-time":"2026-02-17T05:43:17Z","timestamp":1771306997380,"version":"3.50.1"},"reference-count":80,"publisher":"Wiley","issue":"S2","license":[{"start":{"date-parts":[[2022,9,20]],"date-time":"2022-09-20T00:00:00Z","timestamp":1663632000000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"content-domain":{"domain":["onlinelibrary.wiley.com"],"crossmark-restriction":true},"short-container-title":["American J Hematol"],"published-print":{"date-parts":[[2022,11]]},"abstract":"<jats:title>Abstract<\/jats:title><jats:p>Treatment options with targeted agents have changed the treatment landscape of CLL profoundly. Besides chemoimmunotherapy, treatment regimen approved for frontline therapy include continuous treatment with BTK inhibitors like ibrutinib and acalabrutinib or fixed\u2010duration regimen like venetoclax\u2010obinutuzumab with the approval of venetoclax\u2010ibrutinib to be awaited. Although these agents have usually manageable side effects, toxicities might limit choices for the individual patient. We here discuss latest trial data and propose a treatment algorithm for frontline treatment of CLL according to fitness and relevant genetic risk factors like IGHV mutational status and TP53 aberrations.<\/jats:p>","DOI":"10.1002\/ajh.26677","type":"journal-article","created":{"date-parts":[[2022,9,20]],"date-time":"2022-09-20T10:54:50Z","timestamp":1663671290000},"update-policy":"https:\/\/doi.org\/10.1002\/crossmark_policy","source":"Crossref","is-referenced-by-count":5,"title":["Management of front line chronic lymphocytic leukemia"],"prefix":"10.1002","volume":"97","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-9559-8575","authenticated-orcid":false,"given":"Nadine","family":"Kutsch","sequence":"first","affiliation":[{"name":"Department I of Internal Medicine, Center for Integrated Oncology Aachen Bonn Cologne, Duesseldorf and German CLL Study Group University of Cologne  Cologne Germany"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Anna Maria","family":"Fink","sequence":"additional","affiliation":[{"name":"Department I of Internal Medicine, Center for Integrated Oncology Aachen Bonn Cologne, Duesseldorf and German CLL Study Group University of Cologne  Cologne Germany"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Kirsten","family":"Fischer","sequence":"additional","affiliation":[{"name":"Department I of Internal Medicine, Center for Integrated Oncology Aachen Bonn Cologne, Duesseldorf and German CLL Study Group University of Cologne  Cologne Germany"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"311","published-online":{"date-parts":[[2022,9,20]]},"reference":[{"key":"e_1_2_9_2_1","unstructured":"Surveillance Epidemiology and End Result Program (SEER) of the National Cancer Institute.Cancer stat facts: NHL \u2010 chronic lymphiocytic leukemia.2022. Accessed May 04 2022.https:\/\/seer.cancer.gov\/statfacts\/html\/cllsll.html"},{"key":"e_1_2_9_3_1","doi-asserted-by":"publisher","DOI":"10.1038\/nrclinonc.2010.167"},{"key":"e_1_2_9_4_1","doi-asserted-by":"publisher","DOI":"10.1016\/S1470-2045(16)30029-8"},{"key":"e_1_2_9_5_1","doi-asserted-by":"publisher","DOI":"10.1002\/hon.51_2880"},{"key":"e_1_2_9_6_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.cell.2019.06.011"},{"key":"e_1_2_9_7_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.annonc.2020.09.019"},{"key":"e_1_2_9_8_1","doi-asserted-by":"publisher","DOI":"10.1002\/ajh.26367"},{"key":"e_1_2_9_9_1","doi-asserted-by":"publisher","DOI":"10.1182\/asheducation-2017.1.338"},{"key":"e_1_2_9_10_1","doi-asserted-by":"publisher","DOI":"10.1200\/EDBK_279099"},{"key":"e_1_2_9_11_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2014-10-604272"},{"key":"e_1_2_9_12_1","doi-asserted-by":"publisher","DOI":"10.1080\/10428194.2017.1375110"},{"key":"e_1_2_9_13_1","doi-asserted-by":"publisher","DOI":"10.1111\/bjh.14324"},{"key":"e_1_2_9_14_1","doi-asserted-by":"publisher","DOI":"10.3324\/haematol.2017.171041"},{"key":"e_1_2_9_15_1","doi-asserted-by":"publisher","DOI":"10.3324\/haematol.2021.278901"},{"key":"e_1_2_9_16_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.critrevonc.2021.103238"},{"key":"e_1_2_9_17_1","doi-asserted-by":"publisher","DOI":"10.3324\/haematol.2015.126672"},{"key":"e_1_2_9_18_1","doi-asserted-by":"publisher","DOI":"10.3389\/fonc.2021.720704"},{"key":"e_1_2_9_19_1","doi-asserted-by":"publisher","DOI":"10.1182\/hematology.2020000118"},{"key":"e_1_2_9_20_1","doi-asserted-by":"publisher","DOI":"10.1080\/10428194.2020.1768384"},{"key":"e_1_2_9_21_1","doi-asserted-by":"publisher","DOI":"10.1182\/hematology.2020000120"},{"key":"e_1_2_9_22_1","doi-asserted-by":"publisher","DOI":"10.1097\/HS9.0000000000000336"},{"key":"e_1_2_9_23_1","doi-asserted-by":"publisher","DOI":"10.3109\/10428194.2014.957203"},{"key":"e_1_2_9_24_1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1313984"},{"key":"e_1_2_9_25_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2017-09-806398"},{"key":"e_1_2_9_26_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood.2021010845"},{"key":"e_1_2_9_27_1","doi-asserted-by":"crossref","unstructured":"StephensDM MoseleyA HillBT et al.Randomized phase III study of early intervention with venetoclax and obinutuzumab versus delayed therapy with venetoclax and obinutuzumab in newly diagnosed asymptomatic high\u2010risk patients with chronic lymphocytic leukemia\/small lymphocytic lymphoma (CLL\/SLL): evolve CLL\/SLL study (SWOG S1925; NCT#04269902). Paper presented at: ASH Meeting 2021; 2021. Abstract 2630.","DOI":"10.1182\/blood-2021-144780"},{"key":"e_1_2_9_28_1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1509388"},{"key":"e_1_2_9_29_1","doi-asserted-by":"publisher","DOI":"10.1182\/bloodadvances.2021006434"},{"key":"e_1_2_9_30_1","doi-asserted-by":"crossref","unstructured":"MunirT MorenoC OwenC et al.First prospective data on minimal residual disease (MRD) outcomes after fixed\u2010duration ibrutinib plus venetoclax (Ibr+Ven) versus chlorambucil plus obinutuzumab (Clb+O) for first\u2010line treatment of CLL in elderly or unfit patients: the glow study. Paper presented at ASH 2021. Abstract 70.","DOI":"10.1182\/blood-2021-148666"},{"key":"e_1_2_9_31_1","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(20)30262-2"},{"key":"e_1_2_9_32_1","doi-asserted-by":"publisher","DOI":"10.1016\/S1470-2045(18)30788-5"},{"key":"e_1_2_9_33_1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1815281"},{"key":"e_1_2_9_34_1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1817073"},{"key":"e_1_2_9_35_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood.2021014960"},{"key":"e_1_2_9_36_1","doi-asserted-by":"crossref","unstructured":"HillmenP PitchfordA BloorA et al.Ibrutinib plus rituximab is superior to FCR in previously untreated CLL: results of the phase III NCRI FLAIR trial. Paper presented at ASH Meeting 2021. Abstract 642.","DOI":"10.1182\/blood-2021-152319"},{"key":"e_1_2_9_37_1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1812836"},{"key":"e_1_2_9_38_1","doi-asserted-by":"publisher","DOI":"10.3324\/haematol.2021.279012"},{"key":"e_1_2_9_39_1","doi-asserted-by":"publisher","DOI":"10.1038\/s41375-019-0602-x"},{"key":"e_1_2_9_40_1","doi-asserted-by":"publisher","DOI":"10.1080\/10428194.2021.2020779"},{"key":"e_1_2_9_41_1","doi-asserted-by":"publisher","DOI":"10.1038\/s41375-021-01485-x"},{"key":"e_1_2_9_42_1","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.21.01210"},{"key":"e_1_2_9_43_1","doi-asserted-by":"crossref","unstructured":"TamCS GiannopoulosK JurczakW et al.SEQUOIA: results of a phase 3 randomized study of zanubrutinib versus bendamustine + rituximab (BR) in patients with treatment\u2010na\u00efve (TN) chronic lymphocytic leukemia\/small lymphocytic lymphoma (CLL\/SLL). Paper presented at ASH Meeting 2021; 2021. Abstract 396.","DOI":"10.1182\/blood-2021-148457"},{"key":"e_1_2_9_44_1","doi-asserted-by":"publisher","DOI":"10.3324\/haematol.2018.198820"},{"key":"e_1_2_9_45_1","doi-asserted-by":"publisher","DOI":"10.3324\/haematol.2017.182907"},{"key":"e_1_2_9_46_1","doi-asserted-by":"publisher","DOI":"10.1016\/S1470-2045(20)30443-5"},{"key":"e_1_2_9_47_1","doi-asserted-by":"crossref","unstructured":"EichhorstB NiemannC KaterAP et al.A randomized phase III study of venetoclax\u2010based time\u2010limited combination treatments (RVe GVe GIVe) vs standard chemoimmunotherapy (CIT: FCR\/BR) in frontline chronic lymphocytic leukemia (CLL) of fit patients: first co\u2010primary endpoint analysis of the International Intergroup GAIA (CLL13) trial. Paper presented at ASH Meeting 2021; 2021. Abstract 71.","DOI":"10.1182\/blood-2021-146161"},{"key":"e_1_2_9_48_1","unstructured":"EichhorstBNC KaterA F\u00fcrstenauM et al.Time\u2010limited venetoclax\u2010obinutuzumab +\/\u2212 ibrutinib is superior to chemoimmunotherapy in frontline chronic lymphocytic leukemia (CLL): PFS co\u2010primary endpoint of the randomized phase 3 GAIA\/CLL13\u2010trial. Paper presented at EHA 2022; 2022. Abstract LB2365."},{"key":"e_1_2_9_49_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2015-09-667675"},{"key":"e_1_2_9_50_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2015-06-651125"},{"key":"e_1_2_9_51_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood.V94.6.1848"},{"key":"e_1_2_9_52_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2014-01-546150"},{"key":"e_1_2_9_53_1","doi-asserted-by":"publisher","DOI":"10.1038\/nature15395"},{"key":"e_1_2_9_54_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.clml.2019.03.002"},{"key":"e_1_2_9_55_1","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.21.01181"},{"key":"e_1_2_9_56_1","doi-asserted-by":"crossref","unstructured":"SimonF GizaA RobrechtS et al.Pooled analysis of first\u2010line treatment with targeted agents in patients with chronic lymphocytic leukemia (CLL) aged 80\u2009years and older. Paper presented at ASH Meeting 2021; 2021. Abstract 1552.","DOI":"10.1182\/blood-2021-150698"},{"key":"e_1_2_9_57_1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJM200012283432602"},{"key":"e_1_2_9_58_1","doi-asserted-by":"publisher","DOI":"10.1158\/1078-0432.CCR-08-1630"},{"key":"e_1_2_9_59_1","doi-asserted-by":"publisher","DOI":"10.1111\/bjh.17984"},{"key":"e_1_2_9_60_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood.2020010484"},{"key":"e_1_2_9_61_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood.2019004492"},{"key":"e_1_2_9_62_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood.2021012315"},{"key":"e_1_2_9_63_1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMc2005943"},{"key":"e_1_2_9_64_1","doi-asserted-by":"crossref","unstructured":"DavidsMS FischerK RobrechtS et al.ReVenG: a phase 2 study of venetoclax plus obinutuzumab retreatment in patients with relapsed chronic lymphocytic leukemia. Paper presented at ASH Annual Meeting 2021. Abstract 2634.","DOI":"10.1182\/blood-2021-153033"},{"key":"e_1_2_9_65_1","doi-asserted-by":"publisher","DOI":"10.1111\/bjh.15151"},{"key":"e_1_2_9_66_1","unstructured":"FDA.Zydelig prescribing information. Accessed May 04 2022.https:\/\/www.accessdata.fda.gov\/drugsatfda_docs\/label\/2014\/206545lbl.pdf"},{"key":"e_1_2_9_67_1","doi-asserted-by":"publisher","DOI":"10.1002\/ajh.26595"},{"key":"e_1_2_9_68_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood.2020009530"},{"key":"e_1_2_9_69_1","doi-asserted-by":"publisher","DOI":"10.1002\/ajh.25956"},{"key":"e_1_2_9_70_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.bbmt.2016.09.013"},{"key":"e_1_2_9_71_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2014-07-586826"},{"key":"e_1_2_9_72_1","doi-asserted-by":"publisher","DOI":"10.1182\/bloodadvances.2020001956"},{"key":"e_1_2_9_73_1","doi-asserted-by":"publisher","DOI":"10.3389\/fonc.2020.00894"},{"issue":"8","key":"e_1_2_9_74_1","first-page":"789","article-title":"Ibrutinib and venetoclax for first\u2010line treatment of CLL. Reply","volume":"381","author":"Jain N","year":"2019","journal-title":"N Engl J Med"},{"key":"e_1_2_9_75_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood.2021014488"},{"key":"e_1_2_9_76_1","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.21.00807"},{"key":"e_1_2_9_77_1","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.19.00894"},{"key":"e_1_2_9_78_1","doi-asserted-by":"publisher","DOI":"10.1016\/S1470-2045(22)00220-0"},{"key":"e_1_2_9_79_1","doi-asserted-by":"crossref","unstructured":"RogersKA HuangY RuppertAS et al.Three\u2010year follow\u2010up from a phase 2 study of combination obinutuzumab ibrutinib and venetoclax in chronic lymphocytic leukemia. Paper presented at ASH 2020; 2020. Abstract 1305.","DOI":"10.1182\/blood-2020-137655"},{"key":"e_1_2_9_80_1","doi-asserted-by":"publisher","DOI":"10.1016\/S1470-2045(21)00455-1"},{"key":"e_1_2_9_81_1","doi-asserted-by":"publisher","DOI":"10.1016\/S2352-3026(21)00307-0"}],"container-title":["American Journal of Hematology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/pdf\/10.1002\/ajh.26677","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/full-xml\/10.1002\/ajh.26677","content-type":"application\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/pdf\/10.1002\/ajh.26677","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,8,22]],"date-time":"2023-08-22T02:26:42Z","timestamp":1692671202000},"score":1,"resource":{"primary":{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/10.1002\/ajh.26677"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,9,20]]},"references-count":80,"journal-issue":{"issue":"S2","published-print":{"date-parts":[[2022,11]]}},"alternative-id":["10.1002\/ajh.26677"],"URL":"https:\/\/doi.org\/10.1002\/ajh.26677","archive":["Portico"],"relation":{},"ISSN":["0361-8609","1096-8652"],"issn-type":[{"value":"0361-8609","type":"print"},{"value":"1096-8652","type":"electronic"}],"subject":[],"published":{"date-parts":[[2022,9,20]]},"assertion":[{"value":"2022-04-28","order":0,"name":"received","label":"Received","group":{"name":"publication_history","label":"Publication History"}},{"value":"2022-08-01","order":1,"name":"accepted","label":"Accepted","group":{"name":"publication_history","label":"Publication History"}},{"value":"2022-09-20","order":2,"name":"published","label":"Published","group":{"name":"publication_history","label":"Publication History"}}]}}